Connecticut 2017 Regular Session

Connecticut Senate Bill SB00866 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		General Assembly Raised Bill No. 866
2	2		January Session, 2017 LCO No. 4303
3		-	_____~~SB00866GL~~__~~__030817___~~_
	3	+	04303_______GL_
4	4		Referred to Committee on GENERAL LAW
5	5		Introduced by:
6	6		(GL)
7	7
8	8		General Assembly
9	9
10	10		Raised Bill No. 866
11	11
12	12		January Session, 2017
13	13
14	14		LCO No. 4303
15	15
16		-	_____~~SB00866GL~~__~~__030817___~~_
	16	+	04303_______GL_
17	17
18	18		Referred to Committee on GENERAL LAW
19	19
20	20		Introduced by:
21	21
22	22		(GL)
23	23
24	24		AN ACT CONCERNING CANNABIDIOL PRESCRIPTION MEDICATION.
25	25
26	26		Be it enacted by the Senate and House of Representatives in General Assembly convened:
27	27
28	28		Section 1. (NEW) (Effective July 1, 2017) If a cannabidiol investigational product is newly approved or rescheduled by the federal Food and Drug Administration, as a prescription medication, as defined in section 17b-499 of the general statutes, such investigational product shall be deemed approved as a prescription medication in this state.
29	29
30	30
31	31
32	32
33	33		This act shall take effect as follows and shall amend the following sections:
34	34		Section 1 July 1, 2017 New section
35	35
36	36		This act shall take effect as follows and shall amend the following sections:
37	37
38	38		Section 1
39	39
40	40		July 1, 2017
41	41
42	42		New section
43	43
	44	+	Statement of Purpose:
44	45
	46	+	To provide a potential treatment for children and adults with epilepsy.
45	47
46		-	GL Joint Favorable
47		-
48		-	GL
49		-
50		-	Joint Favorable
	48	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]